Information Provided By:
Fly News Breaks for December 30, 2019
GBT
Dec 30, 2019 | 08:22 EDT
Piper Jaffray analyst Danielle Brill said her survey of 40 doctors that treat sickle cell disease found that the initial demand for Oxbryta appears "even more robust" than she anticipated, with a total of 211 Oxbryta prescriptions written since launch just over two weeks ago and the treatment distributed to 105 out of those 211 patients. 100% of the 40 surveyed doctors plan to prescribe Oxbryta in the next three months, added Brill, who said the survey findings reaffirm her view that Oxbryta will be a commercial success. She keeps an Overweight rating on Global Blood Therapeutics shares with a $120 price target.
News For GBT From the Last 2 Days
GBT
Aug 4, 2021 | 12:12 EDT
Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly.  1... To see the rest of the story go to thefly.com. See Story Here
GBT
Aug 4, 2021 | 09:59 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Camping World (CWH) upgraded to Outperform from Neutral at Baird with analyst Craig Kennison saying in an "extremely tight market," Camping World made the most of the inventory shortage to drive record profitability in Q2. 2. BJ's Restaurants (BJRI) upgraded to Buy from Hold at Deutsche Bank with analyst Brian Mullan saying the risk/reward "seems better now" with the stock down 39% from the March high. 3. Gaming and Leisure Properties (GLPI) upgraded to Buy from Neutral at UBS with analyst Robin Farley saying the shares should re-rate on the resilience of the company's tenants and strength of it leases. 4. Under Armour (UAA) upgraded to Overweight from Neutral at JPMorgan with analyst Matthew Boss seeing a favorable risk/reward setup following the stock's 75% underperformance relative to the retail sector over the past 18 months. 5. Global Blood Therapeutics (GBT) upgraded to Buy from Hold at Truist with analyst Joon Lee saying the company's Q2 results were "solid" and the quarter represents a "fundamental shift" for the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GBT
Aug 4, 2021 | 08:24 EDT
Truist analyst Joon Lee upgraded Global Blood Therapeutics to Buy from Hold with a price target of $50, up from $45. The company's Q2 results were "solid" and the quarter represents a "fundamental shift" for the stock, the analyst tells investors in a research note. With about 7K total patients prescribed and two commercial catalysts expected in the first half of FY22, shares of Global Blood Therapeutics will rebound after a year of underperformance, Lee adds.
GBT
Aug 4, 2021 | 05:13 EDT
Truist analyst Joon Lee upgraded Global Blood Therapeutics to Buy from Hold with a $50 price target.